Bay City Capital
Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
Business Model:
Revenue: $8.4M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Bay City Capital Information
Geographic Data
Address: 750 Battery St
City: San Francisco
State: CA
Zip: 94111
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2M
Social
Twitter
Linkedin
Crunchbase
Metrics
7,558,103Website Global Rank
502Website Monthly Traffic
Twitter Followers
Description
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition and agribusiness sector fund.
Contact Phone:
+14156763830
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/1999 | VNUS Medical Technologies | Venture Round | - |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 5/2007 | Vivaldi Biosciences | Series A | 2M |
| 8/2007 | Presidio Pharmaceuticals | Series B | 26M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 12/2002 | Bioren | Seed Round | - |
| 8/2000 | Epocrates | Series B | 35M |
| 8/2002 | Epocrates | Series C | - |
| 1/2018 | Oculis | Series B | 20.5M |
| 10/2014 | SynGen | Venture Round | - |
| 4/2012 | SynGen | Series A | 5M |
| 1/2002 | BioSeek | Venture Round | - |
| 5/2021 | Oculis | Series C | 0 |
| 1/2008 | Aragon Surgical | Series B | 25M |
| 2/2002 | Syntonix Pharmaceuticals | Series B | 35.8M |
| 3/2002 | Reliant Pharmaceuticals | Series C | 160M |
| 11/2000 | Panomics | Seed Round | - |
| 9/2007 | Aciex Therapeutics | Series A | - |
| 11/2009 | CymaBay Therapeutics | Series E | 0 |
| 1/2010 | Merus | Series B | 0 |
| 8/2000 | Intarcia Therapeutics | Venture Round | - |
| 1/1999 | Lexicon Pharmaceuticals | Post-IPO Equity | 0 |
| 10/2013 | Galecto | Series B | 6.3M |
| 2/2011 | Conatus Pharmaceuticals | Series B | 0 |
| 8/2003 | CymaBay Therapeutics | Series A | 27M |
| 5/2017 | Xeris Pharmaceuticals | Series C | 0 |
| 1/2004 | PTC Therapeutics | Series E | 35M |
| 7/2016 | Vtesse | Series A | 17M |
| 9/2000 | Senomyx | Series B | 10M |
| 10/2016 | Bridge Medicines | Venture Round | - |
| 10/2010 | IDEV Technologies | Series D | 46M |
| 6/2017 | Twist Bioscience | Venture Round | 27M |
| 7/2004 | EnteroMedics | Series A | - |
| 9/2010 | EnteroMedics | Post-IPO Equity | 6.3M |
| 3/2007 | Phenomix | Series C | 55M |
| 4/2009 | Sunesis Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2009 | Hyperion Therapeutics | Series C | 60M |
| 4/2014 | Madrigal Pharmaceuticals | Post-IPO Equity | - |
| 6/2013 | Dermira | Series B | 35M |
| 11/2000 | Helios Health | Venture Round | 0 |
| 3/2010 | Ion Torrent | Series C | 37.1M |
| 9/2001 | PTC Therapeutics | Series D | 0 |
| 11/1997 | Maxia Pharmaceuticals | Venture Round | - |
| 1/2006 | MAP Pharmaceuticals | Series C | 25.2M |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 9/2004 | MAP Pharmaceuticals | Series B | 30M |
| 10/2009 | Aviir | Venture Round | 1M |
| 1/2014 | Fabric Genomics (formerly Omicia) | Series A | 6.8M |
| 6/2003 | Phenomix | Series A | 11.6M |
| 6/2013 | Aviir | Series B | 10M |
| 1/2010 | Aviir | Venture Round | 4.2M |
| 1/1998 | Pharminex | Venture Round | - |
| 1/1999 | LJL Biosystems | Post-IPO Equity | - |
| 10/2005 | Radiant Medical | Venture Round | 36M |
| 8/2005 | Protez Pharmaceuticals | Series B | 15M |
| 12/2008 | Aviir | Venture Round | 7.8M |
| 7/2012 | GenturaDx | Series C | 21M |
| 9/2007 | Aviir | Series B | 11.3M |
| 9/2006 | NuPathe | Series A | 15M |
| 10/2003 | Reliant Pharmaceuticals | Series D | 115M |
| 1/2016 | Imara | Seed Round | 800k |
| 11/2012 | Ascendancy | Venture Round | - |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 11/2009 | Calypso Medical | Series E | 50M |
| 3/2007 | MAP Pharmaceuticals | Series D | 50M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 12/2006 | NBI Development | Seed Round | 5.5M |
| 12/2011 | Aviir | Venture Round | 10M |
| 3/2008 | Aviir | Venture Round | 1.5M |
| 10/2020 | Sembiosys Genetics | Venture Round | - |
| 9/2013 | Civitas Therapeutics | Series B | 0 |
| 6/2004 | PTC Therapeutics | Series E | 0 |
| 2/2012 | Altheos | Series A | 12.5M |
| 4/2010 | Altheos | Series A | 20M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 3/2013 | Nabsys | Series D | 35M |
| 4/2016 | Imara | Series A | 31M |
| 7/2004 | Phenomix | Series A | 2M |
| 1/2018 | KBP Biosciences | Series A | 0 |
| 2/2007 | PTC Therapeutics | Series F | 10M |
| 10/2011 | Dermira | Series A | 42M |
| 3/2019 | Imara | Series B | 0 |
| 8/2014 | Civitas Therapeutics | Series C | 0 |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 10/2013 | Merus | Series B | 42.2M |
| 7/2011 | Nevro | Series B | 58M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 4/2015 | Merus | Series C | 79.1M |
| 12/2006 | Nevro | Seed Round | 5.5M |
| 9/2008 | Nevro | Series A | 21.8M |
| 10/2009 | Epizyme | Series B | 32M |
| 8/2014 | Dermira | Series C | 51M |
| 3/2002 | Phenomix | Series A | 12M |
| 10/2002 | Pharmion | Venture Round | 40M |
| 3/2013 | Nevro | Series C | 0 |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 7/2017 | Kezar Life Sciences | Series B | 0 |
| 3/2020 | Xilio Therapeutics | Series B | 100.5M |
| 1/2015 | Vtesse | Series A | 25M |
| 5/2007 | Conatus Pharmaceuticals | Series A | 22M |
| 11/2020 | Bridge Medicines | Equity | 10M |
| 2/2008 | Cadence Pharmaceuticals | Post-IPO Equity | - |
| 11/2018 | NextCure | Series B | 93M |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 2/2013 | Aviir | Series B | 10M |
| 8/2000 | Syrrx | Series A | 5.1M |
| 6/2002 | Itamar Medical | Venture Round | - |
| 7/2008 | NuPathe | Series B | 30M |
| 1/2009 | Vivaldi Biosciences | Series A | 23M |
| 6/2011 | Aviir | Venture Round | 3M |
| 10/2013 | PharmAkea | Series A | 10M |
| 12/2014 | Interleukin Genetics | Post-IPO Equity | 5M |
| 3/2008 | BrainCells | Series B | 30M |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 3/2009 | VIA Pharmaceuticals | Debt Financing | 10M |
| 4/2005 | Phenomix | Series B | 20M |
| 10/2017 | Gritstone Bio | Venture Round | - |
| 4/2012 | Thermogenesis | Post-IPO Equity | - |
| 10/2013 | Cydan | Venture Round | 10M |
| 3/2000 | AquaBounty Technologies | Venture Round | - |
| 12/1997 | Chemdex | Seed Round | - |
| 5/2013 | Interleukin Genetics | Post-IPO Equity | 12M |
| 11/2002 | Pathway Diagnostics | Venture Round | - |
| 4/2000 | Ingenuity Systems | Venture Round | - |
| 7/2005 | BrainCells | Series A | 0 |
| 2/2006 | NeoRX Corporation (Poniard Pharmaceuticals) | Post-IPO Equity | 65M |
| 3/2008 | IDEV Technologies | Series C | 14.4M |
| 3/2009 | Accriva Diagnostics | Venture Round | - |
| 12/2004 | CymaBay Therapeutics | Series B | 44M |
| 5/2021 | Oculis | Series C | 0 |
| 11/2020 | Bridge Medicines | Venture Round | 0 |
| 10/2020 | Sembiosys Genetics | Venture Round | - |
| 3/2020 | Xilio Therapeutics | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 11/2018 | NextCure | Series B | 0 |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 1/2018 | KBP Biosciences | Series A | 0 |
| 1/2018 | Oculis | Series B | 0 |
| 10/2017 | Gritstone Bio | Venture Round | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
